Kabra Drugs Limited (BSE: KABRADG | INE323K01017) has received a Letter of Intent (LOI) from the Government of Chhattisgarh for establishing a pharmaceutical manufacturing facility at Nava Raipur Pharma Park, Chhattisgarh.
Project Details
- Proposed Investment: Approximately ₹200 Crore
- Project Location: Nava Raipur Pharma Park, Chhattisgarh
- Nature of Project: Pharmaceutical Manufacturing Facility and Related Healthcare Manufacturing Activities
- Employment Generation: Approximately 250 direct and indirect opportunities
- Authority: Government of Chhattisgarh
- Date of LOI Receipt: June 12, 2026
Strategic Significance
The project represents a significant milestone in the company's long-term expansion strategy and is expected to:
- Enhance manufacturing footprint
- Strengthen operational capabilities
- Expand production capacity
- Position the company to capitalize on emerging opportunities in pharmaceutical and healthcare manufacturing sectors
The facility will be established at Nava Raipur Pharma Park, a strategically located pharmaceutical manufacturing hub being developed by the Government of Chhattisgarh.
Conditions and Next Steps
The investment proposal remains subject to:
- Execution of definitive agreements
- Receipt of necessary approvals and sanctions
- Compliance with statutory requirements
The company expects to benefit from applicable state government policies, incentives, approvals, and support mechanisms, subject to sanction orders.
Management Commentary
Mr. N. Aravind, Managing Director (DIN: 01895602), stated that the project is aligned with the company's vision of expanding manufacturing capabilities and strengthening presence in the pharmaceutical sector. He emphasized the company's commitment to building a future-ready pharmaceutical platform focused on quality, innovation, and sustainable value creation.
Company Background
Kabra Drugs Limited is a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs. The company maintains WHO-GMP aligned systems and advanced manufacturing capabilities.
Disclaimer
The document contains forward-looking statements subject to risks and uncertainties including government actions, local, political or economic developments, technological risks, and other factors that could cause actual results to differ materially.